Targeting Minority Stressors to Improve Eating Disorder Symptoms in Sexual Minority Individuals With Eating Disorders
Launched by AUBURN UNIVERSITY · Aug 20, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called PRIDE, which aims to help sexual minority individuals (such as those who identify as lesbian, gay, bisexual, or other non-heterosexual identities) who are struggling with eating disorders. The goal is to reduce feelings of shame and stigma related to their sexual orientation and improve their ability to cope with stress. The researchers want to find out if this approach can help improve symptoms of eating disorders in these individuals.
To participate, you need to be between 18 and 65 years old, identify as a sexual minority, and have a diagnosed eating disorder, such as anorexia or bulimia. You should also have experienced discrimination because of your sexual orientation in the past year. Participants will attend up to 14 weekly therapy sessions with trained clinicians, where they will work on both their eating issues and coping strategies. After completing the program, participants will fill out surveys to help researchers understand the treatment's effectiveness. If you're interested and meet the eligibility criteria, this could be a valuable opportunity for support and healing.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age 18 to 65 years
- • identify as lesbian, gay, bisexual, other non-heterosexual identities
- • meet criteria for a Diagnostic and Statistical Manual - 5 (DSM-5) eating disorder (i.e., anorexia nervosa, bulimia nervosa, binge eating disorder, other specified feeding or eating disorder)
- • reports current (past 12 months) experience with discrimination due to sexual orientation;
- • speaks English
- • has internet access and a working webcam
- • reside (and plan to continue to reside for the study duration) in California or one of the Psychology Interjurisdictional Compact (PSYPACT) states
- • able to provide informed consent
- Exclusion Criteria:
- • inability to speak/read English
- • active suicidal plans or intent
- • other major untreated psychiatric diagnoses (e.g., untreated bipolar disorder, untreated psychosis)
- • body mass index below 17.0, a standard clinical cutoff used to denote moderate-severe underweight that may be indicated for a higher level of medical care than standard outpatient treatment
About Auburn University
Auburn University is a leading research institution dedicated to advancing knowledge and improving health outcomes through innovative clinical trials. With a commitment to interdisciplinary collaboration, the university leverages its diverse expertise in health sciences, engineering, and social sciences to conduct rigorous research that addresses pressing healthcare challenges. Auburn University’s Clinical Trials Office ensures adherence to ethical standards and regulatory compliance, facilitating high-quality research that contributes to the scientific community and enhances patient care. Through its robust infrastructure and support services, Auburn University is poised to make significant contributions to clinical research and public health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Diego, California, United States
Auburn, Alabama, United States
Patients applied
Trial Officials
Tiffany Brown, PhD
Principal Investigator
Auburn University
Aaron Blashill, PhD
Principal Investigator
San Diego State University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported